Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer.
Saved in:
| Title: | Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell cancer. |
|---|---|
| Authors: | Burcher KM; Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Bloomer CH; Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Gavrila E; Wake Forest University School of Medicine, Winston-Salem, NC, USA., Kalada JM; Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Chang MJ; Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Gebeyehu RR; Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Song AH; Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Khoury LM; Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Lycan TW; Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.; Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA., Kinney R; Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., D'Agostino R Jr; Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA.; Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA., Bunch PM; Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Shukla K; Section on Molecular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Triozzi P; Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.; Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA., Furdui CM; Section on Molecular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA.; Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA., Zhang W; Center for Cancer Genomics and Precision Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.; Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA., Porosnicu M; Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.; Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2024 Jan 19; Vol. 16, pp. 17588359231217959. Date of Electronic Publication: 2024 Jan 19 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1758-8340 |
|---|---|
| DOI: | 10.1177/17588359231217959 |
